A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment

Journal of Pathology

Volumn 234, Issue 1, 2014, Pages 86-98

  Ellem, Stuart J ^a   Taylor, Renea A ^a   Furic, Luc ^a   Larsson, Ola ^b   Frydenberg, Mark ^a   Pook, David ^a   Pedersen, John ^c   Cawsey, Bree ^a   Trotta, Andrew ^d   Need, Eleanor ^d   Buchanan, Grant ^d   Risbridger, Gail P ^a  

^a MONASH UNIVERSITY   (Australia)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Tissupath Pty Ltd   (Australia)

^d Digestive Disease Research Centre   (Australia)

Author keywords

CXCL12; mast cells; microenvironment; oestrogen; prostate; stroma

Indexed keywords

ANDROGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3; COMPLEMENTARY DNA; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1F6; INTERLEUKIN 22; INTERLEUKIN 8 RECEPTOR; INTERLEUKIN 8 RECEPTOR BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 2; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRYPTASE; UNCLASSIFIED DRUG; VITELLOGENIN; CHEMOKINE; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; CYTOKINE; ESTROGEN RECEPTOR;

ARTICLE; BENIGN FIBROBLAST; CARCINOGENESIS; CARCINOMA ASSOCIATED FIBROBLAST; CELL COUNT; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ESTROGEN ACTIVITY; FIBROBLAST; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GLEASON SCORE; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LNCAP CELL LINE; MALE; MAST CELL; MCF 7 CELL LINE; MICROARRAY ANALYSIS; NORMAL PROSTATIC FIBROBLAST; NUCLEOTIDE SEQUENCE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEREOLOGY; STROMA CELL; TRANSACTIVATION; TRANSCRIPTION REGULATION; TRANSURETHRAL RESECTION; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING; CARCINOMA; CELL COMMUNICATION; CELL MOTION; DNA MICROARRAY; FEEDBACK SYSTEM; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

CARCINOMA; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL12; CHEMOKINES; CYTOKINES; ESTROGENS; FEEDBACK, PHYSIOLOGICAL; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; MALE; MAST CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, CXCR4; RECEPTORS, ESTROGEN; TUMOR MICROENVIRONMENT;

EID: 84905915195     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4386     Document Type: Article

References (57)

1. McNeal JE,. Normal histology of the prostate. Am J Surg Pathol 1988; 12: 619-633.
2. Olumi AF, Grossfeld GD, Hayward SW, et al., Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-5011.
3. Joesting MS, Perrin S, Elenbaas B, et al., Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 2005; 65: 10423-10430.
4. De Marzo AM, Platz EA, Sutcliffe S, et al., Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269.
5. Ribatti D, Ennas MG, Vacca A, et al., Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003; 33: 420-425.
6. Ribatti D, Finato N, Crivellato E, et al., Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol 2005; 193: 1961-1965.
7. Fukushima H, Ohsawa M, Ikura Y, et al., Mast cells in diffuse large B-cell lymphoma; their role in fibrosis. Histopathology 2006; 49: 498-505.
8. Galinsky DS, Nechushtan H,. Mast cells and cancer-no longer just basic science. Crit Rev Oncol Hematol 2008; 68: 115-130.
9. Sari A, Serel TA, Candir O, et al., Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma. BJU Int 1999; 84: 851-853.
10. Nonomura N, Takayama H, Nishimura K, et al., Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 2007; 97: 952-956.
11. Amir T, Pai RR, Raghuveer CV,. Mast cell profile in prostatic lesions. Ind J Med Sci 1998; 52: 507-513.
12. Aydin O, Dusmez D, Cinel L, et al., Immunohistological analysis of mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma compared to benign prostatic hyperplasia. Pathol Res Pract 2002; 198: 267-271.
13. Ellem SJ, Risbridger GP,. Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 2007; 7: 621-627.
14. Kuiper GG, Enmark E, Pelto-Huikko M, et al., Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-5930.
15. McPherson SJ, Ellem SJ, Simpson ER, et al., Essential role for estrogen receptor-β in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 2007; 148: 566-574.
16. McPherson SJ, Hussain S, Balanathan P, et al., Estrogen receptor-β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated. Proc Natl Acad Sci USA 2010; 107: 3123-3128.
17. Ricke WA, McPherson SJ, Bianco JJ, et al., Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor-α signaling. FASEB J 2008; 22: 1512-1520.
18. Risbridger G, Wang H, Young P, et al., Evidence that epithelial and mesenchymal estrogen receptor-α mediates effects of estrogen on prostatic epithelium. Dev Biol 2001; 229: 432-442.
19. Prins GS, Birch L, Couse JF, et al., Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor-α: studies with αERKO and βERKO mice. Cancer Res 2001; 61: 6089-6097.
20. Ellem SJ, Wang H, Poutanen M, et al., Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am J Pathol 2009; 175: 1187-1199.
21. Zhao XJ, McKerr G, Dong Z, et al., Expression of oestrogen and progesterone receptors by mast cells alone, but not lymphocytes, macrophages or other immune cells in human upper airways. Thorax 2001; 56: 205-211.
22. Zaitsu M, Narita S, Lambert KC, et al., Estradiol activates mast cells via a non-genomic estrogen receptor-α and calcium influx. Mol Immunol 2007; 44: 1977-1985.
23. Taylor RA, Toivanen R, Frydenberg M, et al., Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells 2012; 30: 1087-1096.
24. Soucek L, Lawlor ER, Soto D, et al., Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007; 13: 1211-1218.
25. Ellem SJ, Schmitt JF, Pedersen JS, et al., Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004; 89: 2434-2441.
26. Need EF, Scher HI, Peters AA, et al., A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology 2009; 150: 2674-2682.
27. Need EF, Selth LA, Harris TJ, et al., Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor-α in luminal breast cancer cells. Mol Endocrinol 2012; 26: 1941-1952.
28. Vandesompele J, De Preter K, Pattyn F, et al., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: R0034.
29. Toivanen R, Berman DM, Wang H, et al., Brief report: a bioassay to identify primary human prostate cancer repopulating cells. Stem Cells 2011; 29: 1310-1314.
30. Buchanan G, Birrell SN, Peters AA, et al., Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res 2005; 65: 8487-8496.
31. Buchanan G, Yang M, Cheong A, et al., Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 2004; 13: 1677-1692.
32. Jia L, Berman BP, Jariwala U, et al., Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 2008; 3: e3645.
33. Dai S, Zhang Y, Weimbs T, et al., Bacteria-generated PtdIns(3)P recruits VAMP8 to facilitate phagocytosis. Traffic 2007; 8: 1365-1374.
34. Sandberg R, Larsson O,. Improved precision and accuracy for microarrays using updated probe set definitions. BMC Bioinformat 2007; 8: 48.
35. Wright GW, Simon RM,. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003; 19: 2448-2455.
36. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc 1995; 57: 289-300.
37. -ΔΔC t method. Methods 2001; 25: 402-408.
38. Pittoni P, Tripodo C, Piconese S, et al., Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 2011; 71: 5987-5997.
39. Begley LA, Kasina S, Mehra R, et al., CXCL5 promotes prostate cancer progression. Neoplasia 2008; 10: 244-254.
40. Ghadjar P, Loddenkemper C, Coupland SE, et al., Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol 2008; 134: 1181-1189.
41. Ricciardelli C, Choong CS, Buchanan G, et al., Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 2005; 63: 19-28.
42. Henshall SM, Quinn DI, Lee CS, et al., Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001; 61: 423-427.
43. Wikstrom P, Marusic J, Stattin P, et al., Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 2009; 69: 799-809.
44. Lawrence MG, Taylor RA, Toivanen R, et al., A preclinical xenograft model of prostate cancer using human tumors. Nat Protoc 2013; 8: 836-848.
45. Madar S, Brosh R, Buganim Y, et al., Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis 2009; 30: 20-27.
46. Orimo A, Gupta PB, Sgroi DC, et al., Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
47. Ao M, Franco OE, Park D, et al., Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 2007; 67: 4244-4253.
48. Dotan I, Werner L, Vigodman S, et al., CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis 2010; 16: 583-592.
49. Ellem SJ, Risbridger GP,. The dual, opposing roles of estrogen in the prostate. Ann NY Acad Sci 2009; 1155: 174-186.
50. Wang ZQ, Xing WM, Fan HH, et al., The novel lipopolysaccharide-binding protein CRISPLD2 is a critical serum protein to regulate endotoxin function. J Immunol 2009; 183: 6646-6656.
51. Han YF, Cao GW,. Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers. World J Gastroenterol 2012; 18: 6865-6873.
52. Servais C, Erez N,. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J Pathol 2013; 229: 198-207.
53. Orr B, Riddick AC, Stewart GD, et al., Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate. Oncogene 2012; 31: 1130-1142.
54. Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al., A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996; 184: 1101-1109.
55. Kasina S, Macoska JA,. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol 2012; 351: 249-263.
56. Dubrovska A, Elliott J, Salamone RJ, et al., CXCR4 expression in prostate cancer progenitor cells. PLoS One 2012; 7: e31226.
57. Guhl S, Babina M, Neou A, et al., Mast cell lines HMC-1 and LAD2 in comparison with mature human skin mast cells-drastically reduced levels of tryptase and chymase in mast cell lines. Exp Dermatol 2010; 19: 845-847.